Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma

Swiss Med Wkly. 2005 Apr 30;135(17-18):263-5. doi: 10.4414/smw.2005.10963.

Abstract

Immunocompromised patients are at risk of developing Epstein-Barr virus (EBV)-related lymphoproliferative disorders. Quantitative determination of serum EBV DNA permits early diagnosis of an AIDS-related non-Hodgkin's lymphoma, and surveillance of treatment response and/or relapse, and thus may be a useful tool to monitor disease activity.

Publication types

  • Case Reports

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Cyclophosphamide / administration & dosage
  • DNA, Viral / blood*
  • Doxorubicin / administration & dosage
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • Herpesvirus 4, Human / genetics
  • Herpesvirus 4, Human / isolation & purification*
  • Humans
  • Lymphoma, AIDS-Related / complications
  • Lymphoma, AIDS-Related / drug therapy
  • Lymphoma, AIDS-Related / virology*
  • Lymphoma, Non-Hodgkin / complications
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / virology*
  • Male
  • Middle Aged
  • Prednisone / administration & dosage
  • Switzerland
  • Vincristine / administration & dosage

Substances

  • Anti-HIV Agents
  • DNA, Viral
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol